Company / Return on Equity (ROE)
Neogen Return on Equity (ROE) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-34.7%
FY2024
5-year range
-34.7% / 5.8%
FY2020-FY2024
Trend
-11476.7%
vs FY2023
Sector context
#132 of 147
Health Care
What the data says
Neogen reports negative total equity of -34.7% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-34.7% in FY2024 with a 5-year CAGR of -44.0%.
Declined from -2.6% to -34.7% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -40.5pp
- 5-Year Change
- -44.0pp
- 10-Year Change
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 147This company -34.7% Sector average -3.1%
▼
-1012.9% below sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 11476.7% year-over-year.
- Currently 31.6pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -34.7% | -11476.7% |
| FY2023 | -0.3% | +88.4% |
| FY2022 | -2.6% | -144.9% |
| FY2021 | 5.8% | -31.5% |
| FY2020 | 8.4% | -9.9% |
| FY2019 | 9.3% | -13.2% |
| FY2018 | 10.7% | -19.8% |
| FY2017 | 13.4% | +23.6% |
| FY2016 | 10.8% | +3.9% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026